Estrogenic Effect of the Extract of QingYan Formula on Reproductive Tissues in Immature Mice

Yuan Zhao,1 Hong-Xia Zheng,2 Ying Xu3,2 and Na Lin2

1Tianjin University of Traditional Chinese Medicine, Tianjin, China
2Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China

Correspondence should be addressed to Ying Xu; yxu@icmm.ac.cn and Na Lin; nlin@icmm.ac.cn

Received 29 August 2018; Revised 11 November 2018; Accepted 20 December 2018; Published 8 January 2019

Academic Editor: Miguel Vilas-Boas

Copyright © 2019 Yuan Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A Chinese herbal preparation, QingYan formula (QYF), has been used clinically for kidney-invigorating. However, no evidence base links QYF to estrogen replacement therapy. In this study, the estrogenic effects of QingYan formula 70% ethanol extract (QYFE) were investigated in immature mice. Immature mice were treated with QYFE at doses of 1, 2, and 4g/kg for 7 days. QYFE treatments promoted vaginal cornification and prolonged the estrus status of the immature mice, promoted the growth and development of uterus and vagina, upregulated ERα and ERβ expression at protein level in uterus and vagina, increased the level of estradiol (E2), and decreased concentration of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in serum. This study demonstrated that QYFE exerts estrogenic effects by stimulating biosynthesis of estrogen and increasing estrogen receptors (ERs) in target tissues and provided an evidence base for QYFE treatment instead of estrogen replacement therapy.

1. Introduction

Estrogen is a fat-soluble steroid hormone with important implications for the growth, development, and reproduction of human body systems [1]. Maintaining normal levels of estrogen in the body helps maintain women’s reproductive health and general health. Low estrogen levels can lead to sexual dysfunction, endocrine disorders, and menopause. Perimenopausal syndrome is a disease caused by decreased estrogen secretion. However, despite the evidence supporting hormone replacement therapy (HRT) for menopause, many women have opted to discontinue or refuse HRT due to the fear of malignancy, adverse events such as endometrial hyperplasia [2, 3] and cancer [4]. As a consequence, many women are searching for safer alternative treatments to manage their menopausal symptoms. To avoid these side effects, phytoestrogens which are estrogen-like substance derived from foods and plants, such as extracts from soybean and traditional Chinese medicine, have become a new source of estrogen [5]. These phytoestrogens do not simply mimic the effects of human sex hormones but also exhibit similar and divergent actions [6].

The growth, development, maturation, and aging of a woman’s life are closely related to the rising and falling of kidney function (Shen qi) according to traditional Chinese medicine (TCM) theory, and this process is also accompanied by a process in the level of estrogen from a gradual increase in adolescence to a maximum in adulthood and decrease in old age. Estrogen decline in older people and in postmenopausal women has been explained as kidney deficiency in TCM theory. Many classic kidney tonic formulas have been shown to have estrogen-like effects, such as LiuWeiDiHuang pills [7], Qing‘E formula [8], QiBaoMeiRan formula [9–11], ZuoGuiYin decoction [12], and ZuoGuiWan [13].

QingYan formula (QYF) is recorded in the ShengZongLu during Song Dynasty in China and includes Hali-tium, Pricklyash Peel, Morinda officinalis How., Achyranthes bidentata Blume. and Cistanche deserticola Ma. According to ancient book, QYF has been used to prevent and treat various related diseases of kidney dysfunction and strengthen tendon and bone through nourishing kidney. According to ancient book, QYF has been used to prevent and treat various related diseases of kidney dysfunction and strengthen tendon and bone through nourishing kidney. However, there is little knowledge about the estrogenic effects of QYF, especially its link to HRT. The Organization for Economic Cooperation and Development recommends evaluations for...
estrogenic activity to be performed both in immature and ovariectomized (OVX) rats/mice [14]. In present research, we explored estrogenic effects of QEFE by immature mice to identify novel and potent agents for HRT.

2. Materials and Methods

2.1. Preparation of QingYan Formula Extracts. QingYan formula (QYF) is composed of Halitium, Pricklyash Peel, Morinda officinalis How., Achyranthes bidentata Blume. and Cistanche deserticola Ma. at ratio of 1:1.5:2:2:2. All herbs were obtained from Beijing TongRenTang (Beijing, China). QYF was extracted in ethanol/water 70/30 twice, 5 h each time. The solvent ratio was 1:10 w/v for the first time and 1:8 w/v for the second time. The extract was collected by filtration, and the solvent was evaporated under reduced pressure to constant weight. The yield of extraction was 48.9% (w/w).

2.2. Experimental Animals. Female Kunming mice (21-day-old) were obtained from Experimental Animal Center of Academy of Military Medical Sciences (Certificate No. SCXK [Jun] 2012-0004). All animals were housed at 20–22°C under a 12 h light–dark cycle, provided with rodent chow and tap water ad libitum. Animal treatment and maintenance were performed and approved by Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences.

The immature mice were divided into five groups by random number table method. One group received intragastric administration with estradiol valerate (EV, 0.154 mg/kg). The other groups were administered orally at a daily dose of 1, 2, and 4 µg/kg QYF for 7 days. In control group, mice received distilled water only. There were 10 mice in each group. Dose calculations followed guidelines correlating the dose equivalents between humans and laboratory animals on the basis of body surface area.

2.3. Monitoring Vaginal Smear. Vaginal smears were collected for 7 days. Use a pipette to take a small amount of physiological saline and pump it 10 times in vagina. Transfer the cell suspension to the slide and dry it at room temperature. Cells were stained with 95% ethanol and methylene blue for 10 minutes, respectively. Vaginal epithelial cells were observed by microscopy. Keratinized vaginal cells were used to indicate estrus [11, 15], including proestrus, estrus, metoestrus, and diestrus.

2.4. Uterine Index Test. Animals were sacrificed by decapitation after 7 days’ treatment. The uteruses of immature mice were removed and weighed. And then calculate uterine coefficient. Uterine index = wet weight of uterine/mouse body weight × 100%.

2.5. Histology of Uterus and Vagina. The left horns of the uterus and the lower half of vagina were fixed in neutral 10% formalin solution for 24 h at room temperature, then dehydrated using grades of ethanol (80%, 90%, 95%, and 100%), cleared in xylene, embedded in paraffin, and prepared for cross-sections. Hematoxylin and eosin stained 4 micron sections were obtained for microscopy [16].

2.6. Analysis of Serum. Blood sample was drawn from eyeball and the serum after centrifugation was used to analyze estradiol (E2), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) by the means of enzyme linked immunosorbent assay (ELISA) in accordance with instructions. E2, FSH, and LH ELISA kit were obtained from Beijing XinFangCheng Biological Co., Ltd. (Beijing, China). Briefly, all reagents were brought to room temperature (18–26°C) before use. At first, 50µL standard solution or sample was added to the well. Secondly, 100µL horseradish peroxidase-labeled antibody was added and then the board was incubated 1 hour at 37°C, then all the liquid was discarded and the board was washed 5 times. After that, 50µL substrate A and substrate B (1:1) were added to every well, separately, and then the board was incubated at 37°C for 15 minutes in the dark. In the end, 50µL stop solution was added in all wells. OD value was read at 450 nm immediately.

2.7. Immunohistochemistry. Paraffin sections (5 µm) were mounted on polylysine-coated slides, deparaffinized by a routine method, hydrated, and then treated with 3% H2O2 in phosphate-buffered saline for 10 minutes. Each section was incubated with blocking serum (Earthox, Millbrae, USA) at room temperature for 30 minutes and then incubated overnight at 4°C with primary antibody, rabbit antiestrogen receptor-α antibody (dilution 1/200, Abcam Biotechnology, Cambridge, UK), and a rabbit antiestrogen receptor-β (dilution 1/400, Abcam Biotechnology, Cambridge, UK). Negative controls were achieved by sections incubated with PBS without antibody served. The sections were washed three times in 0.5% PBS-T. Then, sections were incubated in avidin-biotin-peroxidase complex for 1h. The sections were visualized with Diaminobenzidine (DAB) (ZhongShanJinQiao Biotechnology Co., Ltd., Beijing, China) and then analyzed by the Image-Pro Plus 6.0 System image analysis system [8, 11, 16–18].

2.8. Western Blot. The right horns of the uterus and vagina were stored at -80°C for western blot. Uterus and vagina were homogenized in RIPA lysis buffer supplemented with aprotinin on the ice for 30 minutes and then centrifuged at 15,000 rpm for 15 minutes at 4°C. Afterward, the supernatant was collected and protein concentration was estimated by Bradford. The dilution ratios of ERα (Abcam Biotechnology, ab32063), ERβ (Abcam Biotechnology, ab3577), and GAPDH (Abcam Biotechnology, ab181602) were 1:1000, 1:2000, and 1:50000, respectively. The blots were developed using an enhanced chemiluminescent assay. All experiments were done in triplicate. Alpha Ease FC (Fluorchem FC2) software was used to measure the relative quantity of each antibody [19].

2.9. Statistics Analysis. SPSS version 11.0 for Windows (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Values shown represent the mean ± SD. Differences between mean values were analyzed using one-way ANOVA followed by S-N-K method. For all cases, significance of differences was accepted at P<0.05.
3. Results

3.1. Effect of QYFE on the Estrus Cycle. In the study, we compared the estrogenic activity of QYFE on the vagina of immature mice with a synthetic estrogen, EV. As shown in Figure 1, untreated immature mice were in diestrus with presenting leukocytes in smears of vaginal epithelium. In contrast, the vaginal cells from the immature mice treated with EV or QYFE at doses of 1, 2, 4 g/kg became keratinized after 5-day treatment, which indicates that immature mice entered the status of estrus earlier than the immature mice untreated. Moreover, treatment with QYFE prolonged the estrous stage of immature mice, suggesting potent estrogenic activity.

3.2. Effect of QYFE on Uterine Weights. Estrogen promotes thickening of the endometrium and leads to uterine weight gain; therefore, estrogen activity can be evaluated by measuring the effect of exogenous estrogen on animal growth and uterine growth. Figure 2 showed that treatment with EV resulted in significant estrogenic activity on the uterus (P < 0.001). QYFE (1, 2, or 4 g/kg) can increase the uterus coefficient, and compared with control group, the difference was statistically significant (P < 0.05 or P < 0.01). However, the extent of increasing is much less than that of EV group. QYFE at the dose of 2 g/kg induced a max uterine weight increase by 1.5-fold compared to untreated immature.

3.3. Effect of QYFE on Levels of Serum E₂, FSH, and LH. Compared with control group, the EV group significantly increased the circulating level of E₂ approximately 90% and decreased the level of LH and FSH by 10% and 6%, respectively. Treatment with 2, 4 g/kg QYFE significantly raised levels of serum E₂ compared to untreated immature mice (P < 0.01 or P < 0.001). The high dose of QYFE (4 g/kg) increased circulating E₂ at 25% compared with untreated immature mice. Meanwhile, 2, 4 g/kg QYFE treatment significantly decreased LH and FSH content in immature mice (P < 0.05).

More specifically, the high dose of QYFE (4 g/kg) resulted in 12.5% decrease in LH and 12.0% decrease in FSH compared with untreated immature mice. These results are illustrated in Figure 3.

3.4. Effects of QYFE on the Histology of Uterus and Vagina. Microscopic preparations of representative uterus and vagina were shown in Figure 4. Histological analysis revealed that treating with EV or QYFE substantially promoted the growth and development of uterus and vagina in immature mice. In Figure 4(a), compared with those of untreated samples, the mouse’s endometrium was markedly thickened, the uterine glands increased, and the uterine cavity expanded in EV groups. QYFE treatment also resulted in thickening endometrium, increased uterine glands, and expanded uterine cavity as that in EV group, but extent was slightly lower. Compared with control group, animals in EV group (Figure 4(b) II) obviously promoted keratinization of the vaginal mucosal epithelium and increased the number of stratified squamous epithelial cells and the number of layers. Treatment with QYFE (1, 2, and 4 g/kg) increased epithelial thickness and also the number of layers. Above all, these
studies improved that QYFE had significant estrogenic activity, similar to EV. These data prompted further studies to elucidate the molecular basis of QYFE activity.

3.5. QYFE Increased the Expressions of ER Subtype in Uterus and Vagina. Figure 5 shows representative sections of the expressions of ERα, ERβ in reproductive tissues from each group and their corresponding quantitative analysis in immature mice. The ERs of uterus in the control group was mainly expressed in endometrium, glandular epithelial cells, and uterine stroma, and ERβ of uterus was mainly distributed in endometrium and glandular epithelial cells. ERs in uterus were expressed in similar cell types in EV or QYFE groups. ERα and ERβ of vagina were mainly distributed in vaginal squamous epithelial cells, keratinized epithelium, stromal fibroblasts, and smooth muscle cells in the control group, and the squamous epithelial cells expressed the strongest. Treatment with either EV or QYFE at any doses significantly increased ERα and ERβ expression in reproductive target tissues more than control group (P < 0.05, P < 0.01, or P < 0.001). The largest increase had been found in the groups of 4 g/kg (P < 0.001). These results further supported the indication that QYFE had very potent estrogenic activity.

3.6. QYFE Increased the Protein Levels of ERs in Uterus and Vagina. Western blot was used to examine protein expression of estrogen receptor subtypes in target tissues treated with EV or QYFE. As shown in Figure 6, EV induced a 1.7- and 0.4-fold increase in ERα and ERβ in uterus than control group and a dose of 4 g/kg QYFE significantly increased the protein expression of ERα by 1.7-fold (p < 0.01) and ERβ by 0.31-fold (p < 0.01). The western blot results of vagina in immature mice clearly showed that, compared with control group, EV induced a 0.78- and 1.0-fold increase in ERα and ERβ of vagina (p < 0.001). Similarly, treatment with QYFE (4 g/kg) stimulated the levels of ERα and ERβ by 6.78- and 2.45-fold, respectively.

4. Discussion

This study aimed to investigate the estrogenic effects and mechanism of QYF on the uterus and vagina in immature mice after short-term administration. Our results suggested that QYFE treatment significantly promoted the developments of uterus and vagina and significantly upregulated ERα and ERβ expressions in reproductive target tissues. Moreover, QYFE could increase levels of circulating E2 while decrease serum LH and FSH levels. These data supports that QYFE's estrogenic activity may be mediated by stimulating biosynthesis of estrogen and upregulating ERα and ERβ expressions in target tissues.

Uterine coefficient is a gold standard widely used in evaluating estrogenic activity in vivo. Estrogen can promote thickening of the endometrium [20], lead to uterine weight gain [21], and promote keratinization of the vaginal epidermal cells [22]. In present research, QYFE treatment promoted sexual maturation as indicated by increasing uterine weight, thickening the uterine endometrium, advancing estrous cycle, and increasing vaginal epithelial layers. Increased uterine weight and the number of keratinization of vaginal epithelial cells are consistent with the idea that E2 has uterotrophic effects. The findings indicate that QYFE has potent estrogenic activity on reproductive tissues of immature mice.

Estrogen is a steroid hormone which can promote the development of vaginal and cervix, vaginal epithelial hyperplasia, and keratinization. Estrogen has positive feedback regulation on the hypothalamus and pituitary gland. It can affect gonadotropin levels in the hypothalamus and pituitary glands. The synthesis and secretion of estrogen directly inhibit the secretion of the alpha subunit of gonadotropin and the beta subunit of FSH and LH by the pituitary gland. Estrogen promotes repairation and hyperplasia of the endometrium, increases blood supply to the myometrium, promotes uterine smooth muscle cell proliferation, and thickens the muscle layer. From the increased serum estrogen
concentration and decreased FSH and LH concentration, it can be hypothesized that QYFE may play a central role by mediating the hypothalamus-pituitary-ovary axis, stimulating biosynthesis of estrogen in the ovary and negative feedback of GnRH production in the hypothalamus [23, 24], which suggests the short-loop effect of QYFE directly on hypothalamus.

Under physiological conditions, estrogen effect is not only related to estrogen content but also closely related to the number, subtypes, and distribution of estrogen receptors.
Figure 5: Effect of QingYan formula extract (QYFE) on expression of estrogen receptor (ER) subtype in the uterus and vagina in immature mice. ERs expressions were assessed by immunohistochemistry. Representative photomicrographs taken at 200-X magnification in the uterus and 400-X magnification in the vagina. (a) ERs expression of uterus in immature mice. ERs expressed in the epithelial cells of the endometrium, interstitial cells, and smooth muscle cells in the uterus. (b) ERs expression of vagina in immature mice. ERs were expressed in the vaginal epithelium cells of squamous and smooth muscle cells in vagina. Data are the mean and standard deviation from 10 mice. *P values are for the one-way analysis of variance comparing the treatment group with untreated immature mice. Treatment groups are shown: (I) control group; (II) treated with estradiol valerate (EV); (III) treated with QYFE (1 g/kg); (IV) treated with QYFE (2 g/kg); (V) treated with QYFE (4 g/kg). ***P < 0.001, **P < 0.01, and *P < 0.05 compared with the control group.
Figure 6: Effect of QingYan formula extract (QYFE) on protein levels of estrogen receptor (ER) subtype in the uterus and vagina in immature mice. Western blot analysis of ER subtype expression in uterus and vagina was carried out as described in Materials and Methods. (a) Protein expression levels of ERs in the uterus; (b) protein expression levels of ERs in the vagina. Representative blots are shown in the above. Quantitative analysis of expression is shown in the below. *P values are for one-way analysis of variance (ANOVA) comparing treatment groups with untreated immature mice. **P < 0.001, ***P < 0.01, and *P < 0.05 compared with the control group.

(ERs) on target organs [25]. Estrogen works by binding to a high-affinity nuclear receptor (ER). Previous studies have shown that ERα mediates estrogen-driven proliferation of the normal breast, uterine, and vagina in puberty [26–28]. In present research, QYFE significantly upregulated the expressions of ERα and ERβ in reproductive tissues, respectively, and promoted the development of the reproductive target tissues.

In summary, QYFE might have the effect of promoting the development of reproductive tissues of immature mice, and QYFE’s estrogenic activity may play a role by stimulating estrogen biosynthesis and increasing the number of ER in target organs. These novel findings may shed light on the development of QYFE or its estrogenic compounds as an efficient and safe drug candidate in therapy of menopausal syndrome. In the future work, we will further explore its effect in the treatment of perimenopausal syndrome and molecular mechanism.

Data Availability
The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.

Conflicts of Interest
No conflicts of financial interests exist.

Acknowledgments
This research was financially supported by the project of National Natural Science Foundation of China (81573632, 81774203) and the Fundamental Research Funds for the Central Public Welfare Research Institutes (zxkt17015).

References
[1] A. Kumar, A. Banerjee, D. Singh et al., “Estradiol: a steroid with multiple facets,” Hormone and Metabolic Research, vol. 50, no. 05, pp. 359–374, 2018.
[2] D. Xin, H. Wang, J. Yang et al., “Phytoestrogens from Psoralea corylifolia reveal estrogen receptor-subtype selectivity,” Phytomedicine, vol. 17, no. 2, pp. 126–131, 2010.
[3] E. Fernandez, S. Gallus, C. Bosetti, S. Franceschi, E. Negri, and C. La Vecchia, “Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies,” International Journal of Cancer, vol. 105, no. 3, pp. 408–412, 2003.
[4] K. H. Humphries and S. Gill, “Risks and benefits of hormone replacement therapy: The evidence speaks,” Canadian Medical Association Journal, vol. 168, no. 8, pp. 1001–1010, 2003.
[5] Y. Dong, A. Jiang, H. Yang, H. Chen, and Y. Wang, “Phytoestrogen α-zearalanol improves memory impairment and hippocampal neurogenesis in ovariectomized mice,” The Scientific World Journal, vol. 2014, Article ID 862019, 6 pages, 2014.
[6] L. Li, X. Chen, C. C. Liu, L. S. Lee, C. Man, and S. H. Cheng, “Phytooestrogen bakuchiol exhibits in vitro and in vivo anti-breast cancer effects by inducing S phase arrest and apoptosis,” Frontiers in Pharmacology, vol. 7, pp. 1–14, 2016.
[7] W. Limopasmanee, S. Chansakaow, N. Rojanasthien, M. Manorot, C. Sangdee, and S. Teekachunhatean, “Effects of the Chinese Herbal Formulation (Liu Wei Di Huang Wan) on the Pharmacokinetics of Isoflavones in Postmenopausal Women,” BioMed Research International, vol. 2015, Article ID 902702, 8 pages, 2015.
[8] Y. Xu, Z.-J. Zhang, F. Geng et al., “Treatment with Qing’E, a kidney-invigorating Chinese herbal formula, antagonizes the estrogen decline in ovariectomized mice,” Rejuvenation Research, vol. 13, no. 4, pp. 479–488, 2010.

[9] Y. Xu, X. Ma, J. An et al., “Treatment with QiBaoMeiRan, a Chinese herbal formula, prevents bone loss in ovariectomized rat,” Climacteric, vol. 19, no. 1, pp. 98–106, 2016.

[10] Y. Xu, X.-P. Ma, J. Ding et al., “Short-time QiBaoMeiRan formula treatment exerts estrogenic activities without side effects on reproductive tissues in immature mice,” Scientific Reports, vol. 5, pp. 1–13, 2015.

[11] Y. Xu, X. Ma, J. An et al., “Treatment with qi bao mei ran, a kidney-invigorating Chinese herbal formula, antagonizes estrogen decline in ovariectomized rats,” Rejuvenation Research, vol. 17, no. 4, pp. 372–381, 2014.

[12] W. Zhao, H.-X. Wen, H.-L. Zheng, S.-X. Sun, D.-J. Sun, and J. Ni, “Action mechanism of Zuo Gui Yin Decoction’s promotion on estradiol production in rats during the peri-menopausal period,” Journal of Ethnopharmacology, vol. 134, no. 1, pp. 122–129, 2011.

[13] N. Lai, Z. Zhang, and B. Wang, “Regulatory effect of traditional Chinese medicinal formula Zuo-Gui-Wan on the Th17/Treg paradigm in mice with bone loss induced by estrogen deficiency,” Journal of Ethnopharmacology, vol. 166, pp. 228–239, 2015.

[14] J. Kanno, L. Onyon, J. Haseman, P. Fenner-Crisp, J. Ashby, and W. Owens, “The OECD program to validate the rat uterotrophic bioassay to screen compounds for in vivo estrogenic responses: Phase 1,” Environmental Health Perspectives, vol. 109, no. 8, pp. 785–794, 2001.

[15] D. Jie, X. Ying, M. Xiaoping et al., “Estrogenic effect of the extract of Renshen (Radix Ginseng) on reproductive tissues in immature mice,” Journal of Traditional Chinese Medicine, vol. 35, no. 4, pp. 460–467, 2015.

[16] Y. Xu, J. Ding, X.-P. Ma, Y.-H. Ma, Z.-Q. Liu, and N. Lin, “Treatment with Panax Ginseng antagonizes the estrogen decline in ovariectomized mice,” International Journal of Molecular Sciences, vol. 15, no. 5, pp. 7827–7840, 2014.

[17] Y. Xu, J. Ding, J. An et al., “Effect of the interaction of veratrum nigrum with panax ginseng on estrogenic activity in vivo and in vitro,” Scientific Reports, vol. 6, no. 1, Article ID 26924, 2016.

[18] Y. Lin, Y. Xu, E. Shang et al., “Evaluating the influence of veratum nigrum to panax ginseng based on uniform design,” Medical Plant, vol. 5, pp. 3–8, 2014.

[19] Y. Xu, T. Chen, X. Li et al., “Salvia miltiorrhiza bunge increases estrogen level without side effects on reproductive tissues in immature/ovariectomized mice,” AGING, vol. 9, no. 1, pp. 156–172, 2017.

[20] P. Plaza-Parrochia, C. Romero, L. Valladares, and M. Vega, “Endometrium and steroids, a pathologic overview,” Steroids, vol. 126, pp. 85–91, 2017.

[21] D. Gallo, G. F. Zannoni, M. Fabrizi, I. de Stefano, E. Mantuano, and G. Scambia, “Comparative effects of 17β-estradiol and phytoestrogens in the regulation of endometrial functions in the rodent uterus,” Journal of Endocrinological Investigation, vol. 31, no. 1, pp. 48–56, 2008.

[22] P. D. Gupta, S. Vijayasaradhi, and A. G. Reddy, “Keratinization of rat vaginal epithelium. III. Effect of estradiol on keratinization,” Biology of the Cell, vol. 65, no. 3, pp. 281–289, 1989.

[23] P. Micovic, C. K. Soma, and K. Sinchak, “Neuroprogerosterone: Key to estrogen positive feedback?” Brain Research Reviews, vol. 57, no. 2, pp. 470–480, 2008.